ARCHIVES

Phase II Imbruvica Trial Shows 47% of MCL Patients Alive at 27-Month Median Follow-up

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | December 26, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Phase II Trial Tests Vaccine Plus Hormone Therapy For Recurrent Prostate Cancer

August 26, 2005

NCI Budget for FY 1977 Would Halt New Research

January 23, 1976

Solomon Gard’s Questions/Answers

January 2, 1981

House Launches Probe of NCI Spending On Cancer Communications, Education

April 12, 2013

House Medicare Reform Bill Takes A smaller Bite In Drug Reimbursement

June 20, 1997

Markup Completed On Senate Cancer Act Renewal; Waxman Agrees To $90 Million Centers Line Item

May 2, 1980